Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, the company distributes generic and branded pharmaceutical products primarily to independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics, and physician offices. Further, it develops a portfolio of breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. The company has licensing agreement with Assembly Biosciences, Inc.; Mimetogen Pharmaceuticals, Inc.; Almirall, S.A; Naurex, Inc.; and Merck & Co. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:AGN
CUSIP01849010
Phone862-261-7000
Debt
Debt-to-Equity Ratio0.36
Current Ratio1.10
Quick Ratio0.94
Price-To-Earnings
Trailing P/E Ratio10.55
Forward P/E Ratio10.68
P/E Growth1.26
Sales & Book Value
Annual Sales$15.94 billion
Price / Sales3.65
Cash Flow$39.2215 per share
Price / Cash4.38
Book Value$207.19 per share
Price / Book0.83
Profitability
EPS (Most Recent Fiscal Year)$16.35
Net Income$-4,125,500,000.00
Net Margins-11.94%
Return on Equity8.53%
Return on Assets5.00%
Miscellaneous
Employees17,800
Outstanding Shares339,060,000
Market Cap$59,627.73
Allergan (NYSE:AGN) Frequently Asked Questions
What is Allergan's stock symbol?
Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."
How often does Allergan pay dividends? What is the dividend yield for Allergan?
Allergan declared a quarterly dividend on Thursday, May 3rd. Shareholders of record on Friday, May 18th will be given a dividend of $0.72 per share on Friday, June 15th. This represents a $2.88 annualized dividend and a yield of 1.68%. The ex-dividend date is Thursday, May 17th. View Allergan's Dividend History.
How will Allergan's stock buyback program work?
Allergan declared that its Board of Directors has approved a share buyback program on Tuesday, September 26th 2017, which allows the company to buyback $2,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 2.8% of its stock through open market purchases. Stock buyback programs are generally a sign that the company's board believes its stock is undervalued.
How were Allergan's earnings last quarter?
Allergan plc (NYSE:AGN) posted its quarterly earnings results on Monday, April, 30th. The company reported $3.74 EPS for the quarter, beating analysts' consensus estimates of $3.36 by $0.38. The business had revenue of $3.67 billion for the quarter, compared to analyst estimates of $3.59 billion. Allergan had a negative net margin of 11.94% and a positive return on equity of 8.53%. The business's revenue for the quarter was up 2.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.35 earnings per share. View Allergan's Earnings History.
When is Allergan's next earnings date?
What guidance has Allergan issued on next quarter's earnings?
Allergan updated its FY18 earnings guidance on Monday, April, 30th. The company provided EPS guidance of $15.65-16.25 for the period, compared to the Thomson Reuters consensus EPS estimate of $15.66. The company issued revenue guidance of $15.15-15.35 billion, compared to the consensus revenue estimate of $15.24 billion.Allergan also updated its Q2 guidance to $4.00-4.20 EPS.
What price target have analysts set for AGN?
21 equities research analysts have issued twelve-month price objectives for Allergan's stock. Their predictions range from $160.07 to $265.00. On average, they expect Allergan's stock price to reach $212.1616 in the next twelve months. This suggests a possible upside of 23.5% from the stock's current price. View Analyst Ratings for Allergan.
What is the consensus analysts' recommendation for Allergan?
21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 6 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Allergan stock?
Here are some recent quotes from research analysts about Allergan stock:
- 1. According to Zacks Investment Research, "Allergan boasts dominant growth franchises across several therapeutic areas. Key products like Botox and Linzess and new products such as Viberzi, Namzaric and Vraylar will continue to support sales. Allergan also boasts a strong branded pipeline with meaningful data readouts expected in 2018. Biosimilars also represent significant opportunity. In late 2017, Allergan announced cost-cutting efforts to protect it from potential revenue declines. Allergan’s share price has picked up in 2018 after underperforming the industry in the second half of 2017. However, 2018 could prove to be a tough year with the company facing loss of exclusivity for many products including Namenda XR and Restasis. Also, new competition for key growth drivers, Restasis and Linzess, is a concern. Estimates have gone up slightly of the Q2 earnings release. The company has a positive record of earnings surprises in recent quarters." (7/20/2018)
- 2. Mizuho analysts commented, "We raise PT to $176 from $150 on stronger Botox expectations in both migraine and cosmetic indications, and view recent investor activism as positive to AGN." (6/8/2018)
- 3. Cantor Fitzgerald analysts commented, "This morning AGN reported a high quality 1Q18 EPS beat and raised its 2018 EPS guidance. This is clearly good news for the company, but we would note that a beat and raise was widely anticipated by the Street since AGN’s setup looked conservative heading into the year. Furthermore, if Restasis generics do not enter the market in 2018, we could see AGN continuing to beat its financial guidance throughout the year." (4/27/2018)
Who are some of Allergan's key competitors?
Some companies that are related to Allergan include Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Shire (SHPG) and Vertex Pharmaceuticals (VRTX).
Who are Allergan's key executives?
Allergan's management team includes the folowing people:
- Mr. Brenton L. Saunders, Chairman, Pres & CEO (Age 48)
- Mr. William Meury, Exec. VP & Chief Commercial Officer (Age 50)
- Dr. C. David Nicholson, Exec. VP and Chief R&D Officer (Age 63)
- Mr. Matthew M. Walsh, Exec. VP & CFO (Age 51)
- Mr. Wayne R. Swanton, Exec. VP of Global Operations (Age 50)
Has Allergan been receiving favorable news coverage?
Media stories about AGN stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Allergan earned a daily sentiment score of 0.12 on Accern's scale. They also gave news stories about the company an impact score of 47.08 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are Allergan's major shareholders?
Allergan's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Factory Mutual Insurance Co. (0.20%), Retirement Systems of Alabama (0.11%), Confluence Investment Management LLC (0.10%), Bank of Montreal Can (0.10%), Swedbank (0.07%) and Gateway Investment Advisers LLC (0.07%). Company insiders that own Allergan stock include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh, Nesli Basgoz, Paul Bisaro and William Meury. View Institutional Ownership Trends for Allergan.
Which institutional investors are selling Allergan stock?
AGN stock was sold by a variety of institutional investors in the last quarter, including Swedbank, Bank of Montreal Can, Meag Munich Ergo Kapitalanlagegesellschaft MBH, Hartford Investment Management Co., American National Bank, Gofen & Glossberg LLC IL, First National Bank of Omaha and Steward Partners Investment Advisory LLC. View Insider Buying and Selling for Allergan.
Which institutional investors are buying Allergan stock?
AGN stock was bought by a variety of institutional investors in the last quarter, including Cornerstone Wealth Management LLC, Retirement Systems of Alabama, Rhenman & Partners Asset Management AB, Neville Rodie & Shaw Inc., Factory Mutual Insurance Co., Foundry Partners LLC, Assenagon Asset Management S.A. and Fred Alger Management Inc.. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.
How do I buy shares of Allergan?
Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Allergan's stock price today?
One share of AGN stock can currently be purchased for approximately $171.79.
How big of a company is Allergan?
Allergan has a market capitalization of $59.63 billion and generates $15.94 billion in revenue each year. The company earns $-4,125,500,000.00 in net income (profit) each year or $16.35 on an earnings per share basis. Allergan employs 17,800 workers across the globe.
How can I contact Allergan?
Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]
MarketBeat Community Rating for Allergan (NYSE AGN)
MarketBeat's community ratings are surveys of what our community members think about Allergan and other stocks. Vote "Outperform" if you believe AGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
